BALFX
Price
$41.06
Change
+$0.10 (+0.24%)
Updated
Jun 2 closing price
Net Assets
278.87B
PABYX
Price
$18.18
Change
+$0.06 (+0.33%)
Updated
Jun 2 closing price
Net Assets
3.16B
Interact to see
Advertisement

BALFX vs PABYX

Header iconBALFX vs PABYX Comparison
Open Charts BALFX vs PABYXBanner chart's image
BALFX vs PABYX Comparison Chart in %
View a ticker or compare two or three
VS
BALFX vs. PABYX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BALFX is a Hold and PABYX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
BALFX has more cash in the bank: 279B vs. PABYX (3.16B). PABYX pays higher dividends than BALFX: PABYX (2.79) vs BALFX (1.75). BALFX was incepted earlier than PABYX: BALFX (25 years) vs PABYX (32 years). PABYX (0.65) is less costly to investors than BALFX (0.61). PABYX is a more actively managed with annual turnover of: 158.00 vs. BALFX (50.00). PABYX has a lower initial minimum investment than BALFX: PABYX (0) vs BALFX (250). BALFX annual gain was more profitable for investors over the last year : 17.70 vs. PABYX (14.58). BALFX return over 5 years is better than : 35.27 vs. PABYX (13.43).
BALFXPABYXBALFX / PABYX
Total Expense Ratio0.610.6594%
Annual Report Gross Expense Ratio0.610.6594%
Fund Existence25 years32 years-
Gain YTD9.6737.216134%
Front LoadN/AN/A-
Min. Initial Investment2500-
Min. Initial Investment IRAN/AN/A-
Net Assets279B3.16B8,835%
Annual Yield % from dividends1.752.7963%
Returns for 1 year17.7014.58121%
Returns for 3 years45.4336.91123%
Returns for 5 years35.2713.43263%
Returns for 10 years85.7958.83146%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CZNC20.940.24
+1.18%
Citizens & Northern Corp
SVACU11.24-0.03
-0.22%
Spring Valley Acquisition Corp III
UHS142.55-2.14
-1.48%
Universal Health Services
SCYX5.10-0.23
-4.32%
SCYNEXIS Inc
STOK28.68-1.79
-5.87%
Stoke Therapeutics